The first portion of this paper is devoted to an overview of the normal function of the hypothalamo-pituitary-thyroid axis. This section emphasizes areas of current research interest and it identifies several sites and mechanisms that are potentially important interfaces with toxins or toxic mechanisms. We then describe an in vitro technique for the continuous superfusion of enzymatically dispersed pituitary cells; this approach is particularly valuable in studying the dynamics of the TSH responses to the factors known (or suspected) to regulate TSH secretion in vivo. Using this technique, we have found that 10M prostaglandin (PG)I2
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stimulates TSH secretion without altering the response to TRH (10'M), and that this stimulation is not due to its rapid conversion to 6-keto PGF1,,. In contrast PGs of the E series (PGE1 and PGE2, 10M) increase responsiveness to TRH but have no effect alone. We found no effects of any of the other prostanoids tested (PGs A2, B2, Fla, F2a, thromboxanes A2 and B2, and the endoperoxide analog, U-44069. Somatostain (109M) inhibits TRH-induced TSH secretion, but does not alter the responsiveness to PGI2. These findings suggest that somatostatin blocks TSH secretion at a point that is functionally prior to the involvement of the PGs, and perhaps does so by blocking synthesis or limiting availability of selected PGs.
I have chosen a title for this paper that reflects my perception of the twofold mission I have been given. First, I will use this initial paper ofthe session as a "stage setter" in that I will review the basic physiology of the thyroid axis and how its components interact under normal conditions. For the benefit of those who are not actively involved in research in this area, I will try to update the topic by pointing out areas of particular current research interest. My second goal is to emphasize, and to document by reference or presentation of data, certain aspects of the thyroid axis that are not likely to be covered by subsequent speakers. This presentation will not be laden with data concerning endocrine toxicity, but it is hoped that it will serve to identify a number of critical points in this 
I
It is particularly germane to this symposium to point out that the monodeiodination of T4 to either T3 or reverse T3 may be viewed as a branch point that has the potential to function as a very powerful peripheral regulator of the thyroid state. Consequently, this is one rather obvious place for toxicologists to direct their energies in the study of the toxicity of the thyroid axis.
Before proceeding upward in the system depicted in Figure 1 , I should point out the great likelihood of the effects of toxins at another site in the periphery, namely, at the interaction between the thyroid hormones and their binding proteins in serum. Normally, these honnones are predominantly (i.e., greater than 99%) bound to these proteins. If, as most believe, only the free fraction of these hormones is active, then shifts in binding without other compensation can result in changes in the thyroid state. Many drugs are already known to alter the protein binding of thyroid hormones, and certainly any other foreign compound (or toxin) should be considered in this light as well.
Although these events located "below" the thyroid in a functional sense are incredibly important in the overall regulation of the thyroid axis, they do not detract from the importance of factors that alter secretion by the thyroid itself since this gland provides not only a portion of the active hormone pool, but it also provides all substrate for the peripheral deiodination. Of course, under normal physiological conditions, the rate of secretion by the thyroid is primarily determined by the concentration of TSH to which it is exposed. In a moment, I will return to the results of some recent experiments dealing with the factors that regulate TSH secretion. Before that, and consistent with my mission, I would like to point out that a number of factors other than TSH can also alter thyroid secretion. Recognizing that there may be overlap within the list, and with the primary mechanism (TSH), some factors worth mentioning are the following: (1) immunoglobulins-in particular, the immunoglobulin associated with Grave's disease which stimulates all aspects of thyroid hormone synthesis and secretion, probably via cyclic AMP; (2) iodine; (3) drugs--numerous antithyroid drugs act at various sites within the thyroid hormone cascade; (4) diet-of primary concern are the iodine mentioned above and the so-called "goitrogens" found in some foodstuffs; (5) adrenergic nerves-at least in animal studies, it seems clear that norepinephrine from never terminals within the thryroid can activate thyroid hormone secretion; (6) hormones other than TSH-for example, estrogens and glucocorticoids, which may exert their effects via binding proteins and/or TSH; and (7) age- April 1981 there are several interesting transients in thyroid hormone levels during the pre-and neonatal period, and other more gradual changes throughout life into old age. In addition to these factors which we might classify as extrathyroidal factors, we should also consider intrathyroidal factors such as cyclic nucleotides, prostaglandins, and polyamines. These are actually suspected mediators of TSH action. Unfortunately, the associated biochemistry and physiology is still loaded with uncertainty in spite of much current research activity (2) . In any case, any toxicity relating to the economy of these ubiquitous substances might well be expected to affect thyroid function.
Regulation of Thyrotropin Secretion: Superfusion of Enzymatically Dispersed Pituicytes I would now like to turn to the regulation of the secretion of the primary controller of thyroid function, i.e., TSH. This hormone is secreted by the anterior pituitary, and is under the influence of three humoral factors. The first of these is the negative feedback inhibition by thyroid hormones arriving via the systemic circulation (Fig. 1) . In addition, there are two hypothalamic hormones that arrive via the hypothalamo-hypophyseal portal vessels which can alter TSH secretion; thyrotropin releasing hormone (TRH) stimulates TSH secretion, and somatostatin (SRIF) inhibits TSH secretion. I must emphasize the significance of this latter vascular connection which arises in the region of the medial basal hypothalamus as a capillary plexus, and terminates only a short distance away in the sinusoids of the anterior pituitary. Experimentally, it is often necessary to distinguish between a pituitary and a suprapituitary site of action of some substances. As you might imagine, this very closely coupled series configuration often complicates such experiments. In attempting to surmount this problem several years ago, we (3) and others (4) addressed the anterior pituitary directly by a stereotaxic approach, and still others (5) have used a more demanding approach of placing a micropipet into a single portal vessel. However, our recent efforts in this regard have been concerned with an in vitro system which we feel has a number of advantages over the classical static incubation of hemipituitaries.
We have established a system for the continuous superfusion of enzymatically dispersed anterior pituitary cells (Fig. 2) . This system has some elements in common with those described by Lowry (6), Schrey et al. (7), and Mulder and Smelik (8) These findings are consistent with the results from other laboratories (9, 10) . Thus the effects of somatostatin and TRH that I have described agree with the depiction in Figure  1 . However, this does not address the issue of physiological roles for these two peptides in regulating TSH secretion. Perhaps the best evidence to support such roles comes from passive immunization studies from other laboratories. For example, it has been shown that the administration of TRH antiserum to conscious rats blocks the cold-induced TSH response, suggesting that endogenous TRH is involved in mediating this response (11) . Similarly, the administration of somatostatin antiserum enhances both basal and TRH-stimulated TSH secretion, providing some evidence for a physiological role for this peptide as well (12) .
Effects of Prostaglandins on Thyrotropin Secretion
Our primary interest in somatostatin and TRH in this superfusion system is in their usefulness as tools to help us define more clearly the roles of other substances thought to be involved in regulating TSH secretion. Recently, we have been particularly interested in using this approach to follow-up our earlier in vivo studies of the roles for prostaglandins (PGs) in regulating pituitary secretion (13) . This earlier work concentrated on the so-called stable PGs typified by those of the E series and the F series. Since that time, numerous new members of the prostanoid family have been recognized, such as the endoperoxide intermediates (PGG2 and PGH2), prostacyclin (PGI2), and the thromboxanes (14) . Thus, we have recently used our in vitro system to investigate some of these prostanoids in relation to pituitary secretion in general; I will present some of our findings regarding TSH in particular.
One of the primary findings is that prostacyclin can stimulate TSH release on its own, but it leaves the responsiveness to TRH relatively unaffected.
This can be seen in each of the three panels of Figure 5 , the left of which makes use of our standard superfusion medium containing bovine serum albumin (BSA). The other two experiments were performed at a time at which we suspected that protein in the medium was inhibiting the effect of the prostacyclin. Since this was true only if the prostacyclin solutions were prepared well in advance of the experiment, we soon circumvented this problem by using only freshly prepared prostacyclin solutions. Thus, the patterns of responses seen in the three panels of Figure 5 (Fig. 6) . The magnitude of this effect is rather small, but it is seen repeatedly and is consistent with our previous in vivo studies (13) , and with the reports of others using static in vitro systems (15, 16) . Although not shown here, the effect of PGE1 is virtually identical to the effect shown in Figure 6 , both qualitatively and quantitatively. The effects described for prostacyclin and PGs of the E series are quite specific in that a number of other prostanoids tested in exactly the same way have been found to be totally ineffective. Figure 7 Studies in the author's laboratory were supported in part by USPHS Grants AM21348 and AM07312.
